AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Tuesday 27 October 2026
News from the 24 hours to Tuesday morning, 27 October 2026.
Tone of the day
+9.2strongly positive
+9.2
Relevant headlines35
Stories8
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Most coverage covered very favourable late-stage cancer results presented at ESMO 2026, chiefly for the stomach cancer drug and for Imfinzi and Tagrisso, along with plans to seek approval and supportive broker comments. The tone was tempered slightly by a postponement of results from the PACIFIC-9 lung trial and by some comparisons with rivals.
What drove it
- ESMO cancer trial data
- gastric cancer ADC
- PACIFIC-9 delay
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Wed 21 Oct | +8.7 | 38 |
| Thu 22 Oct | +8.3 | 28 |
| Fri 23 Oct | +8.3 | 32 |
| Sat 24 Oct | +9.2 | 8 |
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
| Tue 27 Oct | +9.2 | 35 |
8 stories · 35 headlines · strongest first
Pharma and healthcare on 27 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Phase III: AstraZeneca's sone-ve gives gastric cancer patients twice the survival +10.013 headlines today · 28 in all, since 26 October · AstraZeneca's CLDN18.2 antibody-drug conjugate cut death risk and improved survival in late-stage gastric cancer. | ||
| +10.0 | Gastric drug markedly improves survival in later-line patients. | |
| +10.0 | Late-stage study shows survival doubled with stomach cancer drug. | |
| +10.0 | Experimental gastric drug doubles survival in study. | |
| +10.0 | Stomach cancer trial results give patients hope, favourable coverage. | |
| +10.0 | Large mortality reduction in gastric Phase III study. | |
| +10.0 | ADC data comes in ahead of analyst hopes. | |
| +10.0 | Late-stage trial shows survival gain for gastric drug. | |
| +10.0 | Advanced gastric cancer study shows meaningful reduction in mortality. | |
| +10.0 | Gastric cancer ADC data strengthens competitive position. | |
| +10.0 | Positive trial outcome leads to plans for regulatory filing. | |
| +10.0 | Two favourable data releases at the same conference. | |
| +7.5 | Sizeable sales potential noted, with one caveat. | |
| +2.5 | Gastric ADC rivalry with Takeda mentioned within a news roundup. | |
| AstraZeneca shows its oncology pipeline at the 2026 ESMO congress +8.16 headlines today · 10 in all, since 26 October · At ESMO 2026, AstraZeneca presented cancer results and held an update for investors. | ||
| +10.0 | Three cancer medicines produced favourable late-stage results. | |
| +10.0 | Company showcases strong oncology data at major conference. | |
| +10.0 | Company gearing up to file for approval of new therapy. | |
| +9.7 | Broad oncology progress presented at major conference. | |
| +8.3 | Commentary praising late-stage results across several tumour types. | |
| +4.2 | Shares in focus around conference presentation. | |
| Imfinzi regimens cut death risk in lung and bladder cancer +8.15 headlines today · 13 in all, since 25 October · Imfinzi combinations reduced death risk in lung and bladder cancer studies. | ||
| +10.0 | Imfinzi shows large mortality benefits in lung and bladder studies. | |
| +10.0 | Better survival in stomach and lung cancer studies. | |
| +8.3 | Combination with Amgen shows encouraging survival in hard lung cancer. | |
| +6.7 | Strong trial result ahead of upcoming earnings. | |
| +5.0 | Bladder cancer benefit shown, though a competitor's regimen performed better. | |
| Savolitinib added to Tagrisso reduces mortality risk for MET-driven lung cancer +8.23 headlines today · 10 in all, since 26 October · A lung cancer trial found that combining Tagrisso with savolitinib reduced the chance of dying by 32%. | ||
| +10.0 | Combination therapy lowers mortality in lung cancer study. | |
| +9.2 | Partnered lung cancer treatment slows disease progression. | |
| +3.3 | Positive Tagrisso data but rival claims it was first. | |
| AstraZeneca Q3 results preview for 30 October +3.43 headlines today · 4 in all, since 24 October · Previews look ahead to AstraZeneca's 30 October results. | ||
| +4.2 | Pipeline strength seen as possible support before results. | |
| +0.8 | Preview of upcoming quarterly results, no verdict yet. | |
| +0.3 | Scheduled results date announcement, purely factual. | |
| Barclays and JP Morgan keep Buy on AstraZeneca +7.32 headlines today · Barclays and JP Morgan maintained Buy ratings on AstraZeneca. | ||
| +7.5 | Broker keeps bullish stance on the shares. | |
| +7.0 | Analyst retains positive rating and price target. | |
| AstraZeneca PACIFIC-9 trial data delayed to H1 2027 −6.12 headlines today · Results from the PACIFIC-9 study in lung cancer are now expected in the first half of 2027. | ||
| −6.3 | Data timing for lung cancer study slips by a long stretch. | |
| −5.8 | Trial readout pushed back to 2027, a setback for AZN's lung programme. | |
| AstraZeneca enlists Oracle for AI help with recruiting trial participants +5.81 headline today · 39 in all, since 20 October · AstraZeneca is working with Oracle on AI for clinical trial enrolment. | ||
| +5.0 | Technology collaboration aimed at speeding trial recruitment. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.